Introductory Chapter: Multiple Myeloma in the Era of Novel Therapeutics

Al-Anazi, Khalid Ahmed

doi:10.5772/intechopen.82174

Update on Multiple Myeloma 2019

DOI: 10.5772/intechopen.82174

|View full text |Cite

Introductory Chapter: Multiple Myeloma in the Era of Novel Therapeutics

Khalid Ahmed Al-Anazi¹

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Book1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

An Update on Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma

Al-Anazi¹,

Alshaibani²,

Kalogianidis³

2023

Recent Updates on Multiple Myeloma

View full text Add to dashboard Cite

Over the past two decades, treatment of multiple myeloma (MM) has advanced dramatically. However, despite the introduction of several lines of novel therapeutics, autologous hematopoietic stem cell transplantation (HSCT) followed by maintenance therapy is the current standard of care in transplant eligible patients. Autologous HSCT can be performed with or without cryopreservation with equivalent short-term and long-term outcomes. In patients with MM, performance of autologous HSCT at outpatient setting is safe, feasible and has a number of advantages such as saving hospital beds and reducing treatment costs. Autologous HSCT can be safely performed in patients with MM having renal dysfunction or failure although particular attention should be made to the timing of administering medications and stem cells with respect to hemodialysis and dose reduction of specific medications according to creatinine clearance. Tandem autologous HSCT is of value in younger patients with adverse cytogenetics and extramedullary disease. Allogeneic HSCT is the only potentially curative therapeutic modality in MM, but it can only be performed in a small fraction of highly selected patients due to the relatively high treatment-related morbidity and mortality. Despite its valuable role in the treatment of MM, autologous HSCT has its own short-term as well as long-term complications.

show abstract

An Update on Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma

Al-Anazi¹,

Alshaibani²,

Kalogianidis³

2023

Recent Updates on Multiple Myeloma

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Introductory Chapter: Multiple Myeloma in the Era of Novel Therapeutics

Cited by 1 publication

References 82 publications

An Update on Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma

An Update on Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma

Contact Info

Product

Resources

About